California reports more illnesses in people who drank raw milk. Here are the risks, according to health expertsH&M CELEBRATES NEW STORE WITH CHRISTINA AGUILERA NEW YORK , Nov. 21, 2024 /PRNewswire/ -- Today at noon, H&M celebrated the reopening of its iconic Times Square flagship, located at 1472 Broadway, with a special appearance and ribbon cutting ceremony with global pop superstar Christina Aguilera . The refined space, featuring elevated aesthetics and materials, includes immersive experiences showcasing the very best of the brand's fashion identity. At the time of opening, the store will showcase a variety of fashion-forward collections including the H&M Studio Holiday Capsule, which was launched in select stores and online today, offering a modern take on partywear. The store caps off a season of investment and reignited direction for the Swedish brand in its U.S. home of New York City . "I am so excited to be here at H&M's gorgeous new store, in Times Square no less," said Christina Aguilera . "What perfect timing for this location to reopen with their new collection just before the start of the holiday season. We're very excited to bring on the joy for the season!" This fall, H&M celebrates the launch of its most impressive season of fashion yet, which will be on full display at the new Times Square store. The fully redesigned flagship is an elevated, dynamic space featuring women's and men's collections, including special shop-in-shop destinations for H&M Move, the brand's sport offering, as well as denim, lingerie, and accessories. The location will also carry clothing for children ranging from newborn to 10 years old. "H&M debuted in the US nearly 25 years ago with a flagship location in New York City . As a pivotal city for our brand, we continue to invest in our NYC stores to ensure they remain cutting-edge and inspirational to our ever-evolving customer," says Michael Beaumont , Regional Head of Expansion for H&M Americas. "With this refreshed flagship store, customers will be able to see and feel H&M's strengthened brand identity firsthand through hyper-curated artistic and design elements, innovative technologies, and interactive experiences — all anchored by H&M's diverse fashion offerings." The focus on customer experience is reflected in the brand-new immersive fitting area, a first in North America , where fashion lovers can explore trends, try on looks, and bring their style dreams to life. The fitting rooms, a first offer a customizable, multi-sensory experience with LED screens in the floor and ceiling, along with interactive mirrors. Customers can express themselves by selecting visual themes and music based on their style choices and moods, making the shopping experience more personalized and engaging. With visuals and music curated specifically for the new store, these rooms will also encourage customers to create and share their own content. "Our Times Square location is an amazing new space for customers to interact with our brand as well as each other," says Linda Li , Head of Customer Activation and Marketing for H&M Americas. "Features like our new immersive fitting rooms combine music, fashion and fun to let our customers become their own style star." The redesigned flagship showcases impressive new design features like an iconic glass wall flanking each side of the main escalator, designed by Denver based agency, Hovercraft. This signature piece combines art and technology into a multi-story ambient light display, providing customers with a dazzling show on their way to the upper levels. Other interior upgrades include fluted concrete panels, seamless terrazzo flooring, custom built wood fitting rooms and two enormous LED screens on the ground and second floor. Contact: mediarelations.us@hm.com For more images of the opening and new store, click here . For more information from the H&M group and press images visit hmgroup.com/media View original content to download multimedia: https://www.prnewswire.com/news-releases/hm-reopens-iconic-times-square-flagship-in-new-york-city-as-new-brand-showcase-302313611.html SOURCE H&M
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. FATE , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation," said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization." FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ", the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ", the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Taylor Swift is facing the first real test of her relationship with Travis Kelce as her Eras tour comes to an end, here's what it is3D World is a leading software development company known for its groundbreaking solutions in the realm of three-dimensional technology. Leveraging its expertise in 3D visualization and advanced software development, the company has recently unveiled its latest innovation - the 3D World Low-Code Platform. What sets this platform apart from its competitors is the fact that it has been entirely self-developed, from concept to execution, by the team at 3D World.
Title: Data Center Fire? Alibaba Responds!Advisor to the Chief Minister of Balochistan for Women Development, Dr. Rubaba Khan Buledi, has emphasized the need to accelerate efforts for women's rights and development to build a democratic and socially robust Balochistan. Speaking at a workshop organized in collaboration with the Women Development Department and the WHO, she called for comprehensive policy-level actions to empower women. "Gender equality is not just a goal but the foundation of our development," she stated, adding that a better social system can be achieved when women are granted equal rights and opportunities. COMMENTS Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our
Taylor Swift has been captivating fans worldwide with her record-breaking Eras Tour over the past 21 months. As the tour concludes, Swift is preparing for a significant shift in her life. Reports suggest she plans to take a break from the spotlight during the festive season and into 2025, offering her a chance to unwind and embrace new personal endeavors. However, this period may coincide with an emotional comedown, as the closure of such a monumental chapter could bring challenges for the pop icon. Travis Kelce’s Busy NFL Schedule At the same time, Travis Kelce, a key player for the Kansas City Chiefs, is entering the crucial phase of the NFL season. With the Chiefs aiming for an ambitious third consecutive Super Bowl victory, Kelce’s schedule is packed with intense practices and games. This demanding pursuit of a championship title could limit the time he spends with Swift during her transitional period. Their ability to balance these professional and personal demands is being closely observed. Also Read : Fast X: Part 2: All you may want to know Support Amid Challenges: What’s Next? Friends of the couple believe this moment offers an opportunity for Swift to embrace a new chapter, possibly even considering starting a family with Kelce. Despite the challenges posed by their busy lives, Kelce remains supportive, standing by her side during the emotional close of her tour. Meanwhile, the Chiefs continue their strong run this season with a 10-1 record, making their Super Bowl aspirations a reality. Also Read : Big and final insult to Benjamin Netanyahu? Biden picks up anti-Israel book during Black Friday shopping, author says 'it's too late' FAQs: What is the challenge Taylor Swift and Travis Kelce are facing in their relationship? Taylor Swift is concluding her Eras Tour, a monumental 21-month journey, while Travis Kelce enters the most critical phase of his NFL season with the Kansas City Chiefs. This overlap in schedules may test their ability to balance personal and professional commitments. Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Microsoft Word Mastery: From Beginner to Expert By - CA Raj K Agrawal, Chartered Accountant View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Leadership Business Storytelling Masterclass By - Ameen Haque, Founder of Storywallahs View Program Leadership Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) AI for Everyone: Understanding and Applying the Basics on Artificial Intelligence By - Ritesh Vajariya, Generative AI Expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Crypto & NFT Mastery: From Basics to Advanced By - CA Raj K Agrawal, Chartered Accountant View Program Why is this period being considered an emotional test for Taylor Swift? Closing the Eras Tour marks a significant chapter in Swift’s career, potentially leaving her in an emotional transition period. The end of such a major project could bring a sense of void, especially as she adjusts to life off the stage. (You can now subscribe to our Economic Times WhatsApp channel )
Best Bets for NCAA Basketball Picks Against the Spread for Thursday, December 12FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransConTM hGH for ...